Physician profile
Neha Seth
NPI 1235393992
$1,831.39
in general payments reported to CMS, 2019-2025
21 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $74.78 · 2022: $239 · 2023: $275 · 2024: $429 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $293.05 | 2022-2025 | Cuvitru, Gattex |
| Genzyme Corporation | $233.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.56 | 2021-2025 | Tezspire, Fasenra, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $167.88 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $126.65 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $124.26 | 2019-2025 | Ruconest |
| Kaleo, INC. | $86.33 | 2022-2024 | Auvi-Q |
| Amgen INC. | $86.00 | 2023-2025 | Tezspire, Actimmune |
| Csl Behring | $71.78 | 2019-2025 | Andembry |
| Grifols USA, LLC | $70.29 | 2022-2023 | Xembify |
| Genentech USA, INC. | $65.84 | 2024-2025 | Xolair |
| Octapharma USA, INC. | $64.30 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $49.35 | 2025 | Alvesco |
| Phadia US INC. | $43.18 | 2019-2024 | Immunocap |
| Uswm, LLC | $24.60 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $23.54 | 2025 | Nemluvio |
| Shire North American Group INC | $21.92 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $21.71 | 2025 | Neffy |
| Greer Laboratories, INC. | $19.54 | 2025 | Palforzia |
| Circassia INC. | $17.52 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.62 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.